Photo: business-standard.com
Jubilant Pharmova to Invest $300M in US to Boost Injectable Production Capacity
Jubilant Pharmova plans to invest $300 million by FY28 to enhance its sterile injectable production capacity in the US, spurred by tariffs impacting its initial timeline.
- Jubilant HollisterStier LLC, part of Jubilant Pharmova Ltd, will invest $300 million in the US to double its sterile injectable manufacturing capacity by fiscal year 2028.
- The Spokane, Washington facility has launched a new sterile fill and finish line, marking the third line at this site with an investment of $132 million.
- CEO Chris Preti stated that the companys expansion plans were accelerated by President Trumps tariffs, which influenced their approach to increasing production of injection (medicine).
Why It Matters
This investment underscores the growing demand for sterile injectables and reflects how tariff policies can directly impact corporate strategies, shaping the pharmaceutical landscape in the US.